ERBB2 and breast cancer: In this context, the nature of the exosomal microRNA profile of TNBC BC patients has been shown to be different from those of HER2 positive patients in neoadjuvant treatment studies [77], and it has been shown that EVs from certain TNBC cases have the potential to modify the tumor immune microenvironment in favor of an improved prognosis [78].